2017 May 25

Carreras Research and Chemotargets sign a collaboration agreement

Chemotarget's powerful technology will be of great benefit to the Leukaemia Stem Cell Group for their work to develop a drug for acute myeloid leukemia


Barcelona, June 1st, 2017 – The Josep Carreras Leukemia Research Institute announced today that it has entered into a collaboration agreement with Chemotargets. The aim of the collaboration is to further understand the mechanism of action of some active hits in leukemia discovered at IJC and exploit this information to identify new chemical entities with improved pharmacology and safety profiles using Chemotargets’ precision modeling platform.

The research group on acute myeloid leukemia (AML), directed by Dr. Ruth Risueño, published recently a study in which the importance of the serotonin receptor subtypes 1 (HTR1) in AML was highlighted (Etxabe et al. Leukemia 2017). “We observed that AML cells differentially expressed HTR1 compared with healthy blood cells and the most primitive hematopoietic fraction; in fact, HTR1B expression on AML patient samples correlated with clinical outcome”, said Dr. Risueño. “Based on this information, we discovered some hits active on HTR1 and with antileukemia effects; those represent excellent starting points for a drug discovery program and Chemotargets’ platform will be of great help in this process”.

Dr. Jordi Mestres, Chemotargets Founder & CEO commented: “Chemotargets has developed a state-of-the-art analytics and visualization platform that integrates big data in chemistry, pharmacology, toxicology, and therapeutics, combined with novel precision modeling algorithms to predict unknown data in those areas. We are delighted to put our powerful platform at work to accelerate IJC’s drug discovery efforts in the field of AML”

About Josep Carreras Leukemia Research Institute
The Institut Josep Carreras (IJC) carries out research into the basic, epidemiological, preventive, clinical and translational aspects of leukemia and other hematologic malignancies. IJC’s vision is to identify new therapeutic targets to develop more precise and less aggressive leukemia treatments. In doing so, IJC aspiration is to understand the origin and development of leukemias and other malignant hematological pathologies in order to be able to prevent them.

About Chemotargets
Chemotargets S.L. is a computationally-oriented biotech company focused on the drug discovery and development areas. Located in Barcelona, it was founded on March 2006 as a spin-off initiative from the Chemogenomics Laboratory under the auspices of the IMIM Hospital del Mar Medical Research Institute. Chemotargets’ goal is to offer a novel integrated knowledge-based platform to fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and making them more cost-efficient.